Endometriosis: the ongoing quest for therapeutic modulators to prevent cardiovascular adverse outcomes
This paper reviews therapeutic modulators for endometriosis, focusing on their potential to prevent associated cardiovascular adverse outcomes.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Full text
962 characters
· extracted from
epmc-fulltextxml
· 2 sections
· click to expand
Funding
Contrib Info
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
References (2)
Source provenance
- europepmc
- last seen: 2026-08-08T06:08:32.324769+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pmc
- last seen: 2026-05-13T20:22:03.195721+00:00
- pubmed
- last seen: 2026-08-08T06:05:31.577018+00:00